Current pharmacological solutions for Behçet’s syndrome

References

• Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis. 2018 Jun;77(6):808–818.
   PubMed Web of Science ®Google Scholar
• Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003 Jan;82(1):60–76.
   PubMed Web of Science ®Google Scholar
• Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behcet’s disease. Haematologica. 1980 Jun;65(3):399–402.
   PubMed Web of Science ®Google Scholar
• Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet’s syndrome. Arthritis Rheum. 2001 Nov;44(11):2686–2692.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behcet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19(5):542–549.
   PubMed Web of Science ®Google Scholar
• Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med. 1990 Feb 1;322(5):281–285.
   PubMed Web of Science ®Google Scholar
• Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet’s Syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016 Apr;95(16):e3348.
   PubMed Web of Science ®Google Scholar
• Jung YS, Cheon JH, Hong SP, et al. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet’s disease. Inflamm Bowel Dis. 2012 Apr;18(4):750–757.
   PubMed Web of Science ®Google Scholar
• Choi IJ, Kim JS, Cha SD, et al. Long-term clinical course and prognostic factors in intestinal Behcet’s disease. Dis Colon Rectum. 2000 May;43(5):692–700.
   PubMed Web of Science ®Google Scholar
• Lee HW, Cheon JH, Lee HJ, et al. Postoperative effects of thiopurines in patients with intestinal Behcet’s disease. Dig Dis Sci. 2015 Dec;60(12):3721–3727.
   PubMed Web of Science ®Google Scholar
• Ozguler Y, Hatemi G, Cetinkaya F, et al. Clinical course of acute deep vein thrombosis of the legs in Behcet’s syndrome. Rheumatology (Oxford). 2020 Apr 1;59(4):799–806.
   PubMed Web of Science ®Google Scholar
• Girgin S, Yurumez S, Omma A, et al. Comparison of relapse rates in Behcet’s disease with venous involvement on different doses of azathioprine therapy, a retrospective observational study. Int J Rheum Dis. 2021 Apr;24(4):562–566.
   PubMed Web of Science ®Google Scholar
• BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet’s syndrome. Transplant Proc. 1988 Jun;20(3 Suppl 4):136–143.
   PubMed Web of Science ®Google Scholar
• Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet. 1989 May 20;1(8647):1093–1096.
   PubMed Web of Science ®Google Scholar
• Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial. Br J Ophthalmol. 1992 Apr;76(4):241–243.
   PubMed Web of Science ®Google Scholar
• Kötter I, Vonthein R, Schoenfisch B, et al. Interferon alpha2a versus cyclosporin a for the treatment of severe ocular behcet’s disease – a prospective, randomised, single blind, national multicenter trial (INCYTOB). Annual European Congress of Rheumatology; London. 2016;75:1091.
   Google Scholar
• Qian Y, Qu Y, Gao F, et al. Comparison of the safety and efficacy of interferon alpha-2a and cyclosporine-a when combined with glucocorticoid in the treatment of refractory Behcet’s Uveitis: a randomized controlled prospective study. Front Pharmacol. 2021;12:699903.
   PubMed Web of Science ®Google Scholar
• Kose O, Simsek I, Pay S. Mycophenolate sodium in the treatment of mucocutaneous Behcet’s diseases. Int J Dermatol. 2011 Jul;50(7):895–896.
   PubMed Web of Science ®Google Scholar
• Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous adamantiades-Behcet’s disease. Dermatology. 2001;203(4):322–324.
   PubMed Web of Science ®Google Scholar
• Shugaiv E, Tuzun E, Mutlu M, et al. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behcet’s disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S64–7.
   PubMed Web of Science ®Google Scholar
• CE ESN, Hamuryudan V,Z, et al. Mycophenolate Mofetil in the Treatment of Major Organ Involvement of Patients with Behçet’s Syndrome. Annual European Congress of Rheumatology. Madrid. 2019;78:A820.
   Google Scholar
• Saba D, Saricaoglu H, Bayram AS, et al. Arterial lesions in Behcet’s disease. Vasa. 2003 May;32(2):75–81.
   PubMedGoogle Scholar
• Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary arterial aneurysms in Behcet’s syndrome: a report of 24 cases. Br J Rheumatol. 1994 Jan;33(1):48–51.
   PubMedGoogle Scholar
• Noel N, Bernard R, Wechsler B, et al. Long-term outcome of neuro-Behcet’s disease. Arthritis Rheumatol. 2014 May;66(5):1306–1314.
   PubMed Web of Science ®Google Scholar
• Yoon DL, Kim YJ, Koo BS, et al. Neuro-behcet’s disease in South Korea: clinical characteristics and treatment response. Int J Rheum Dis. 2014 May;17(4):453–458.
   PubMed Web of Science ®Google Scholar
• Gurcan M, Esatoglu SN, Hamuryudan V, et al. Long term follow-up of Behcet’s syndrome patients treated with cyclophosphamide. Rheumatology (Oxford). 2020 Sep 1;59(9):2264–2271.
   PubMed Web of Science ®Google Scholar
• Huang MX, Wang CY, Guo JY, et al. Pharmacotherapy for Behcet’s Disease and the Risk of Malignancy. Front Pharmacol. 2021;12:661150.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998 Mar 15;128(6):443–450.
   PubMed Web of Science ®Google Scholar
• Hatemi I, Hatemi G, Pamuk ON, et al. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet’s syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S129–37.
   PubMed Web of Science ®Google Scholar
• Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Behcet’s disease. Mod Rheumatol. 2011 Apr;21(2):184–191.
   PubMed Web of Science ®Google Scholar
• Park J, Cheon JH, Park Y, et al. Efficacy and tolerability of methotrexate therapy for refractory intestinal Behcet’s disease: a single center experience. Intest Res. 2018 Apr;16(2):315–318.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Shahram F, et al. Methotrexate in ocular manifestations of Behcet’s disease: a longitudinal study up to 15 years. Int J Rheum Dis. 2013 Oct;16(5):568–577.
   PubMed Web of Science ®Google Scholar
• Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Behcet’s disease. A follow-up study for 4 years. Adv Exp Med Biol. 2003;528:575–578.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Kikuchi H, Sawada T, et al. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet’s disease. J Neurol Sci. 2015 Feb 15;349(1–2):143–148.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002 Apr;138(4):467–471.
   PubMed Web of Science ®Google Scholar
• Ozguler Y, Leccese P, Christensen R, et al. Management of major organ involvement of Behcet’s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology (Oxford). 2018 Dec 1;57(12):2200–2212.
   PubMed Web of Science ®Google Scholar
• Lightman S, Taylor SR, Bunce C, et al. Pegylated interferon-alpha-2b reduces corticosteroid requirement in patients with Behcet’s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis. 2015 Jun;74(6):1138–1144.
   PubMed Web of Science ®Google Scholar
• Celiker H, Kazokoglu H, Direskeneli H. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behcet’s Uveitis: a Small Case Series. Ocul Immunol Inflamm. 2019;27(1):15–22.
   PubMed Web of Science ®Google Scholar
• Bielefeld P, Devilliers H, Deschasse C, et al. Potential of Pegylated Interferon Alpha-2a in Behcet Uveitis: a Report of Five Cases. Ocul Immunol Inflamm. 2016 Oct;24(5):599–602.
   PubMed Web of Science ®Google Scholar
• Kilic H, Zeytin HE, Korkmaz C, et al. Low-dose natural human interferon-alpha lozenges in the treatment of Behcet’s syndrome. Rheumatology (Oxford). 2009 Nov;48(11):1388–1391.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Yurdakul S, Rosenkaimer F, et al. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behcet’s syndrome: a randomized, double blind trial. Br J Rheumatol. 1991 Oct;30(5):395–396.
   PubMedGoogle Scholar
• Hatemi G, Silman A, Bang D, et al. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis. 2009 Oct;68(10):1528–1534.
   PubMed Web of Science ®Google Scholar
• Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005 Jan;32(1):98–105.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016 Sep 8;375(10):932–943.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016 Sep 17;388(10050):1183–1192.
   PubMed Web of Science ®Google Scholar
• Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behcet’s syndrome: a systematic review for update of the EULAR recommendations for the management of Behcet’s syndrome. Semin Arthritis Rheum. 2019 Feb;48(4):752–762.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Martin-Varillas JL, Calvo-Rio V, et al. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behcet’s Disease: national Multicenter Study of 177 Cases. Arthritis Rheumatol. 2019 Dec;71(12):2081–2089.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between Adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019 Feb;38(2):407–415.
   Google Scholar
• Maalouf G, Andrillon A, Leclercq M, et al. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: a Multicenter Study of 330 Patients. Am J Ophthalmol. 2022 Jun;238:173–180.
   PubMed Web of Science ®Google Scholar
• Esatoglu SN, Akkoc-Mustafayev FN, Ozguler Y, et al. Immunogenicity of Infliximab Among Patients With Behcet Syndrome: a Controlled Study. Front Immunol. 2020;11:618973.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Emmi G, Gentileschi S, et al. Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: a multicenter retrospective observational study. Mod Rheumatol. 2017 Nov;27(6):1031–1035.
   PubMed Web of Science ®Google Scholar
• Vitale A, Emmi G, Lopalco G, et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Behcet’s disease. Clin Rheumatol. 2017 Sep;36(9):2063–2069.
   PubMed Web of Science ®Google Scholar
• Dincses E, Esatoglu SN, Ozguler Y, et al. Biosimilar infliximab for Behcet’s syndrome: a case series. Clin Exp Rheumatol. 2019 Nov-Dec;37(6):111–115.
   PubMed Web of Science ®Google Scholar
• Sota J, Gentileschi S, Perfetti MO, et al. Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behcet’s Syndrome. Ophthalmol Ther. 2021 Dec;10(4):1129–1135.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ebrahimiadib N, Hedayatfar A, et al. Efficacy of Biosimilar Adalimumab in the Treatment of Behcet’s Uveitis. Ocul Immunol Inflamm. 2021;7:1–6.
   Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Rapid loss of efficacy of biosimilar infliximab in three patients with Behcet’s disease after switching from infliximab originator. Eur J Rheumatol. 2017 Dec;4(4):288–290.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Venerito V, Cantarini L, et al. Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behcet’s disease. Intern Emerg Med. 2019 Aug;14(5):719–722.
   PubMed Web of Science ®Google Scholar
• Xue L, van Bilsen K, Schreurs MWJ, et al. Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade((R)) to Remsima((R))? An Observational Study. Front Med (Lausanne). 2020;7:418.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Squatrito D, et al. Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Behcets disease. Semin Arthritis Rheum. 2016 Aug;46(1):e1–2.
   PubMedGoogle Scholar
• Cantarini L, Lopalco G, Vitale A, et al. Paradoxical mucocutaneous flare in a case of Behcet’s disease treated with tocilizumab. Clin Rheumatol. 2015 Jun;34(6):1141–1143.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behcet’s syndrome: report of two cases. Rheumatology (Oxford). 2013 Oct;52(10):1923–1924.
   PubMed Web of Science ®Google Scholar
• Leclercq M, Andrillon A, Maalouf G, et al. Anti-Tumor Necrosis Factor alpha versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: a Multicenter Study from the French Uveitis Network. Ophthalmology. 2022 May;129(5):520–529.
   PubMed Web of Science ®Google Scholar
• Bettiol A, Silvestri E, Di Scala G, et al. The right place of interleukin-1 inhibitors in the treatment of Behcet’s syndrome: a systematic review. Rheumatol Int. 2019 Jun;39(6):971–990.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of Gevokizumab in Patients with Behcet’s Disease Uveitis: an International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study. Ocul Immunol Inflamm. 2018;26(7):1023–1033.
   PubMed Web of Science ®Google Scholar
• Mirouse A, Barete S, Desbois AC, et al. Long-Term Outcome of Ustekinumab Therapy for Behcet’s Disease. Arthritis Rheumatol. 2019 Oct;71(10):1727–1732.
   PubMed Web of Science ®Google Scholar
• Mirouse A, Barete S, Monfort JB, et al. Ustekinumab for Behcet’s disease. J Autoimmun. 2017 Aug;82:41–46.
   PubMed Web of Science ®Google Scholar
• London J, Regent A, Dion J, et al. Efficacy and safety of ustekinumab in Behcet disease: results from the prospective phase 2 STELABEC trial. J Am Acad Dermatol. 2022 Sep;87(3):681–684.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013 Apr;120(4):777–787.
   PubMed Web of Science ®Google Scholar
• Di Scala G, Bettiol A, Cojan RD, et al. Efficacy of the anti-IL 17 secukinumab in refractory Behcet’s syndrome: a preliminary study. J Autoimmun. 2019 Feb;97:108–113.
   PubMed Web of Science ®Google Scholar
• Fagni F, Bettiol A, Talarico R, et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behcet’s phenotype: a multicentre study. Ann Rheum Dis 2020 Aug;79(8):1098–1104.
   PubMed Web of Science ®Google Scholar
• Calleja Algarra A, Aragon Miguel R, Andres Lencina JJ, et al. Behcet’s-like disease during secukinumab treatment: new paradoxical reaction? J Dtsch Dermatol Ges. 2021 Jan;19(1):116–118.
   Web of Science ®Google Scholar
• Barrado-Solis N, Rodrigo-Nicolas B, De la Morena-Barrio I, et al. Report of two cases of Behcet’s disease developed during treatment with secukinumab. J Eur Acad Dermatol Venereol. 2020 Oct;34(10):e587–e589.
   PubMed Web of Science ®Google Scholar
• Dincses E, Yurttas B, Esatoglu SN, et al. Secukinumab induced Behcet’s syndrome: a report of two cases. Oxf Med Case Reports. 2019 May;2019(5):omz041.
   PubMedGoogle Scholar
• Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of Apremilast for Oral Ulcers in Behcet’s Syndrome. N Engl J Med. 2019 Nov 14;381(20):1918–1928.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet’s syndrome–a phase 2, placebo-controlled study. N Engl J Med. 2015 Apr 16;372(16):1510–1518.
   PubMed Web of Science ®Google Scholar
• Iizuka Y, Takase-Minegishi K, Hirahara L, et al. Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Behcet’s disease: a systematic review and meta-analysis. Mod Rheumatol. 2022 Oct 15;32(6):1153–1162.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Mahr A, Takeno M, et al. Impact of apremilast on quality of life in Behcet’s syndrome: analysis of the phase 3 RELIEF study. RMD Open. 2022 Jul;8(2):e002235.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Mahr A, Takeno M, et al. Apremilast for oral ulcers associated with active Behcet’s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. Clin Exp Rheumatol. 2021 Sep-Oct;39-132(5):80–87.
   Web of Science ®Google Scholar
• Vieira M, Buffier S, Vautier M, et al. Apremilast in Refractory Behcet’s Syndrome: a Multicenter Observational Study. Front Immunol. 2020;11:626792.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Martin-Varillas JL, Grana J, et al. Apremilast in refractory orogenital ulcers and other manifestations of Behcet’s disease. A national multicentre study of 51 cases in clinical practice. Clin Exp Rheumatol. 2020 Sep-Oct;38-127(5):69–75.
   Web of Science ®Google Scholar
• Hirahara L, Kirino Y, Soejima Y, et al. Efficacy and safety of apremilast for 3 months in Behcet’s disease: a prospective observational study. Mod Rheumatol. 2021 Jul;31(4):856–861.
   PubMed Web of Science ®Google Scholar
• Liu J, Hou Y, Sun L, et al. A pilot study of tofacitinib for refractory Behcet’s syndrome. Ann Rheum Dis. 2020 Nov;79(11):1517–1520.
   PubMed Web of Science ®Google Scholar
• Zou J, Lin CH, Wang Y, et al. Correspondence on ‘A pilot study of tofacitinib for refractory Behcet’s syndrome’. Ann Rheum Dis. 2021 Jan 25;2020–219810.
   Web of Science ®Google Scholar
• Dincses E, Esatoglu SN, Fresko I, et al. Outcome of invasive procedures for venous thrombosis in Behcet’s syndrome: case series and systematic literature review. Clin Exp Rheumatol. 2019 Nov-Dec;37-121(6):125–131.
   Web of Science ®Google Scholar
• Tuzun H, Seyahi E, Guzelant G, et al. Surgical Treatment of Pulmonary Complications in Behcet’s Syndrome. Semin Thorac Cardiovasc Surg. 2018 Autumn;30(3):369–378.
   PubMed Web of Science ®Google Scholar
• Esatoglu SN, Seyahi E, Ugurlu S, et al. Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behcet’s syndrome patients with pulmonary artery involvement during follow-up. Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):92–96.
   PubMed Web of Science ®Google Scholar
• Yildizeli SO, Yanartas M, Tas S, et al. Outcomes of Patients with Behcet’s Syndrome after Pulmonary Endarterectomy. Thorac Cardiovasc Surg. 2018 Mar;66(2):187–192.
   PubMed Web of Science ®Google Scholar
• Tuzun H, Seyahi E, Arslan C, et al. Management and prognosis of nonpulmonary large arterial disease in patients with Behcet disease. J Vasc Surg. 2012 Jan;55(1):157–163.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Wechsler B, Resche-Rigon M, et al. Cerebral venous thrombosis in Behcet’s disease. Arthritis Rheum. 2009 Apr 15;61(4):518–526.
   PubMedGoogle Scholar
• Hamuryudan V, Hatemi G, Tascilar K, et al. Colchicine in Behcet syndrome: a longterm survey of patients in a controlled trial. J Rheumatol. 2014 Apr;41(4):735–738.
   PubMed Web of Science ®Google Scholar
• Ozyazgan Y, Ucar D, Hatemi G, et al. Ocular Involvement of Behcet’s Syndrome: a Comprehensive Review. Clin Rev Allergy Immunol. 2015 Dec;49(3):298–306.
   PubMed Web of Science ®Google Scholar
• Yang S, Huang Z, Hu Y, et al. The Efficacy of Adalimumab as an Initial Treatment in Patients with Behcet’s Retinal Vasculitis. Front Pharmacol. 2021;12:609148.
   PubMed Web of Science ®Google Scholar
• Emmi G, Vitale A, Silvestri E, et al. Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behcet’s Syndrome: a Retrospective Study of Seventy Patients With Vascular Involvement. Arthritis Rheumatol. 2018 Sep;70(9):1500–1507.
   PubMed Web of Science ®Google Scholar
• Alibaz-Oner F, Vautier M, Aksoy A, et al. Vascular Behcet’s disease: a comparative study from Turkey and France. Clin Exp Rheumatol. 2022 Sep;40(8):1491–1496.
   PubMed Web of Science ®Google Scholar
• Vautier M, Gallien Y, Emmi G, et al. Direct oral anticoagulant for venous thrombosis in Behcet’s syndrome. Autoimmun Rev. 2021 Apr;20(4):102783.
   PubMed Web of Science ®Google Scholar
• Aksoy A, Colak S, Yagiz B, et al. Predictors for the risk and severity of post-thrombotic syndrome in vascular Behcet’s disease. J Vasc Surg Venous Lymphat Disord. 2021 Nov;9(6):1451–1459.
   PubMedGoogle Scholar
• Seyahi E, Cakmak OS, Tutar B, et al. Clinical and Ultrasonographic Evaluation of Lower-extremity Vein Thrombosis in Behcet Syndrome: an Observational Study. Medicine (Baltimore). 2015 Nov;94(44):e1899.
   PubMed Web of Science ®Google Scholar
• Hatemi I, Hatemi G, Celik AF. Gastrointestinal Involvement in Behcet Disease. Rheum Dis Clin North Am. 2018 Feb;44(1):45–64.
   PubMed Web of Science ®Google Scholar
• Esatoglu SN, Hatemi G, Salihoglu A, et al. A reappraisal of the association between Behcet’s disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review. Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S145–51.
   PubMed Web of Science ®Google Scholar
• Yilmaz U, Ar MC, Esatoglu SN, et al. How to treat myelodysplastic syndrome with clinical features resembling Behcet syndrome: a case-based systematic review. Ann Hematol. 2020 Jun;99(6):1193–1203.
   PubMed Web of Science ®Google Scholar
• Jung JY, Kim DY, Bang D. Leg ulcers in Behcet’s disease. Br J Dermatol. 2008 Jan;158(1):178–179.
   PubMed Web of Science ®Google Scholar
• Kecici AS, Polat E, Kutlubay Z. Efficacy of maggot debridement therapy on refractory leg ulcers of Behcet disease: an open-label study. Clin Exp Dermatol. 2021 Jul;46(5):834–841.
   PubMed Web of Science ®Google Scholar
• Guzelant G, Ucar D, Esatoglu SN, et al. Infliximab for uveitis of Behcet’s syndrome: a trend for earlier initiation. Clin Exp Rheumatol. 2017 Nov-Dec;35-108(6):86–89.
   Web of Science ®Google Scholar
• Tukek NB, Esatoglu SN, Hatemi G, et al. Emergence of new manifestations during infliximab treatment in Behçet’s syndrome. Rheumatology (Oxford). 2022 Aug 30;61(9):3746–3753.
   PubMed Web of Science ®Google Scholar
• Kisacik B, Pamuk ON, Onat AM, et al. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-alpha Inhibitors: report from a Large Multicenter Cohort with High Background Prevalence. J Rheumatol. 2016 Mar;43(3):524–529.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Yazici H. Behcet’s syndrome and micro-organisms. Best Pract Res Clin Rheumatol. Best Practice & Research. Clinical Rheumatology. 2011 Jun;25(3):389–406.
   PubMed Web of Science ®Google Scholar
• Emmi G, Bettiol A, Niccolai E, et al. Butyrate-Rich Diets Improve Redox Status and Fibrin Lysis in Behcet’s Syndrome. Circ Res. 2021 Jan 22;128(2):278–280.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Bahar H, Uysal S, et al. The pustular skin lesions in Behcet’s syndrome are not sterile. Ann Rheum Dis. 2004 Nov;63(11):1450–1452.
   PubMed Web of Science ®Google Scholar
• Karaca M, Hatemi G, Sut N, et al. The papulopustular lesion/arthritis cluster of Behcet’s syndrome also clusters in families. Rheumatology (Oxford). 2012 Jun;51(6):1053–1060.
   PubMed Web of Science ®Google Scholar
• Diri E, Mat C, Hamuryudan V, et al. Papulopustular skin lesions are seen more frequently in patients with Behcet’s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis. 2001 Nov;60(11):1074–1076.
   PubMed Web of Science ®Google Scholar
• Pirri S, Talarico R, Marinello D, et al. A systematic literature review of existing tools used to assess medication adherence in connective tissue diseases: the state of the art for the future development of co-designed measurement tools. Reumatismo. 2021 Nov 22;73(3):135–146.
   Web of Science ®Google Scholar
• Pirri S, Marinello D, Lorenzoni V, et al. Adherence to treatment in Behcet’s syndrome: a multi-faceted issue. Clin Exp Rheumatol. 2021 Sep-Oct;39-132(5):88–93.
   Web of Science ®Google Scholar
• Zayed HS, Medhat BM, Seif EM. Evaluation of treatment adherence in patients with Behcet’s disease: its relation to disease manifestations, patients’ beliefs about medications, and quality of life. Clin Rheumatol. 2019 Mar;38(3):761–768.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Meara A, Ozguler Y, et al. Core Set of Domains for Outcome Measures in Behcet’s Syndrome. Arthritis Care Res (Hoboken). 2022 Apr;74(4):691–699.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Meara A, Ozguler Y, et al. Developing a Core Set of Outcome Measures for Behcet Disease: report from OMERACT 2016. J Rheumatol. 2017 Nov;44(11):1750–1753.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Seyahi E, Fresko I, et al. Behcet’s syndrome: a critical digest of the 2013-2014 literature. Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S112–22.
   PubMed Web of Science ®Google Scholar
• Esatoglu SN, Hatemi I, Ozguler Y, et al. Faecal but not serum calprotectin levels look promising in predicting active disease in Behcet’s syndrome patients with gastrointestinal involvement. Clin Exp Rheumatol. 2018 Nov-Dec;36(6 Suppl 115):90–96.
   PubMed Web of Science ®Google Scholar